RecruitingNCT02614911

Characterization of Phenotype and Genotype of Early Onset Enteropathies

Host-Microbiota Interactions Across the Gut Immune System: Characterization of Phenotype and Genotype of Early Onset Enteropathies


Sponsor

Imagine Institute

Enrollment

1,445 participants

Start Date

Jun 16, 2014

Study Type

OBSERVATIONAL

Conditions

Summary

This study has been set up in order to characterize phenotypes and genotypes of patients with early onset enteropathies. In that goal, Investigators will collect biological samples (mainly blood) of patients suffering from early onset enteropathies and their healthy relatives.


Eligibility

Inclusion Criteria3

  • Severe chronic enteropathy
  • Patients developing their first symptoms within the first 6 years of life and, in priority within the first two years of life, or patients with a disease of later onset, in case of a familial history suggestive of inherited mutations notably in families comprising several affected members
  • OR : Be a patient's relative, even if presenting with enteropathy of later onset.

Exclusion Criteria1

  • Subject having participated to any therapeutical clinical study in the 30 days preceding the inclusion in this study,

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiological sampling

Biological sampling including blood, feces, biopsies...


Locations(12)

Centre Hospitalier Pellegrin-Enfants

Bordeaux, France

Hôpital pédiatrique de Lyon

Bron, France

Hôpital Jeanne de Flandre, CHRU de Lille

Lille, France

Hôpital d'enfants de la Timone

Marseille, France

Hôpital Saint Antoine

Paris, France

Necker - Enfants Malades Hospital

Paris, France

Hôpital Robert Debré

Paris, France

Hôpital Trousseau

Paris, France

Hôpital Sud

Rennes, France

CHU Hautepierre

Strasbourg, France

Hôpital des Enfants

Toulouse, France

Hôpital Clocheville, CHU de Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02614911


Related Trials